Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Summary of talimogene laherparepvec responses by lesion-type

From: Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

  Overall tumor response Overall lesion-type response
  Any OR CR Yes
n (%) n (%) n (%) n (%)
Any 37 (100) 14 (37.8) 8 (21.6) 15 (40.5)
At least 1 baseline uninjected lesion 35 (100) 12 (34.3) 6 (17.1) 13 (37.1)
Baseline uninjected non-visceral only 23 (100) 10 (43.5) 5 (21.7) 11 (47.8)
At least 1 visceral lesion at baseline 12 (100) 2 (16.7) 1 (8.3) 2 (16.7)
  1. Denominator is the total number of patients in corresponding patient lesion-type subgroup
  2. Objective response (OR), and complete response (CR) as per investigator-reported responses. Overall lesion response was reported as the proportion of patients with a ≥ 30 % decrease in overall lesion burden. OR was evaluated by modified RECIST.
  3. Overall lesion type response: max decrease ≥ 30 % in overall lesion-type burden from baseline in patient lesion-type subgroup and in total tumor burden for “Any”
  4. All patients received at least one dose of talimogene laherparepvec